Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/5/2026 | Overweight → Sector Weight | KeyBanc Capital Markets | ||
| 2/4/2026 | $1400.00 | Outperform → Neutral | Robert W. Baird | |
| 1/9/2026 | $185.00 | Outperform → Market Perform | BMO Capital Markets | |
| 1/9/2026 | $97.00 | Hold → Buy | TD Cowen | |
| 1/5/2026 | $203.00 | Neutral → Buy | New Street | |
| 12/18/2025 | $100.00 | Neutral → Overweight | Analyst | |
| 12/1/2025 | $200.00 | Overweight → Equal Weight | Barclays | |
| 11/18/2025 | $1775.00 | Outperform | BNP Paribas Exane |
Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial officer, is scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeho
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $
CoreSite, an American Tower company (NYSE:AMT) empowering critical business and AI workloads that impact everyday life through interconnected data center solutions, today announced that CRN®—a brand of The Channel Company—has selected Maile Kaiser, Chief Revenue Officer at CoreSite, for inclusion on the prestigious 2026 CRN® Channel Chiefs list. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. Over the past year through Kaiser's leadership, CoreSite strengthened and diversified its partner ecosystem by onboarding new service providers and technology alliances while developi
KeyBanc Capital Markets downgraded Transdigm Group from Overweight to Sector Weight
Robert W. Baird downgraded Transdigm Group from Outperform to Neutral and set a new price target of $1,400.00
BMO Capital Markets downgraded American Tower from Outperform to Market Perform and set a new price target of $185.00
4 - TransDigm Group INC (0001260221) (Issuer)
4 - TransDigm Group INC (0001260221) (Issuer)
4 - AMERICAN TOWER CORP /MA/ (0001053507) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - TransDigm Group INC (0001260221) (Issuer)
4 - TransDigm Group INC (0001260221) (Issuer)
8-K - TransDigm Group INC (0001260221) (Filer)
8-K - TransDigm Group INC (0001260221) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp
David Sharbutt to lead BitMine's efforts to expand its digital infrastructure capabilities David Sharbutt served 17 years on American Tower's Board (AMT), one of America's largest REITs BitMine is the world's largest ETH Treasury company with Crypto + Cash Holdings Exceeding $9 billion, including 1.79 million ETH Tokens and total cash of $775MM BitMine is supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, and Galaxy Digital to support BitMine's goal of acquiring 5% of ETH: The alchemy of 5% LAS VEGAS, Aug. 28, 2025 /PRNewswire/ -- (NYSE:BMNR) BitMine Immersion Technologies, Inc. ("BitMine" or the
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE:EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most suc
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $
CLEVELAND, Feb. 3, 2026 /PRNewswire/ -- TransDigm Group Incorporated (NYSE:TDG), a leading global designer, producer and supplier of highly engineered aircraft components, today reported results for the first quarter ended December 27, 2025. First quarter highlights include: Net sales of $2,285 million, up 14% from $2,006 million in the prior year's quarter;Net income of $445 million;Earnings per share of $6.62;EBITDA As Defined of $1,197 million, up 13% from $1,061 million in the prior year's quarter;EBITDA As Defined margin of 52.4%Adjusted earnings per share of $8.23, up 5%
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians an